PEGUIS FIRST NATION RETAIL CANNABIS CONDITIONAL APPROVAL BY MANITOBA
WINNIPEG, MB – February 16, 2018: Peguis First Nation Chief Glenn Hudson and his Council are pleased to acknowledge their selection as a member of the consortium that obtained conditional approval by Manitoba for a license to operate retail Cannabis stores in the province. The consortium consists of a partnership between several Manitoba First Nations and National Access Cannabis (NAC) and was formed in anticipation of Bill C-45 which will legalize Cannabis across Canada.
Chief Hudson extends congratulations to all other First Nations in the consortium who were able to secure a conditional license. He noted that this is an immense opportunity for Indigenous Peoples to engage in what is being hailed as the new economy that will bring jobs and other financial spin offs to all Manitobans.
The acceptance of the proposal is conditional upon several factors, including regulatory requirements. The province has conditionally accepted four proposals to operate retail Cannabis stores in Manitoba, with the number of stores and locations still to be determined.
NAC is Canada’s leader in best practices on delivering secure, safe and responsible access to legal medical Cannabis. NAC brings their business systems, branding and economies of scale, central services and managerial support to the partnership. Chief Hudson “looks forward to a long prosperous partnership”, bringing forth a great synergy and creating economic opportunity and prosperity for First Nations people.
Frequently Asked Questions
1. WHERE WILL THE FACILITY BE BUILT, WHERE IS THE LOCATION?
You may have heard that Fuller Road will serve as the location for the Cannabis Production
Facility. It will not. There are a number of locations being reviewed for the production facility in the Winnipeg and Selkirk Industrial areas.
2.WHAT DOES THIS MEAN FOR PEGUIS AND ITS MEMBERS?
First Nations are becoming more and more engaged in the Cannabis Industry nationally.
The unprecedented opportunities will create hundreds of permanent jobs, both on and off-reserve, as well as an equity ownership that will bring additional economic spin-offs to Peguis. The financial benefits include new self-generated revenue to better fund critical community needs, in areas such as: Elder Care, Housing and Health and Wellness services.
3.HOW DOES CANNABIS EFFECT THE DRUG PROBLEMS WE FACE IN OUR COMMUNITIES?
A survey conducted by the Canadian Centre on Substance use and Addiction (CCSA) reported that Alcohol and Drug Abuse were the number one challenges for community wellness faced by on-reserve communities.
Data from 2011 reveals that 55% of drug overdose deaths were related to prescription medications, of which, 75% involved opiate painkillers. Researchers found that opiate-related deaths decreased by approximately 33% in 13 states in the following six years after medical marijuana was legalized.
4. IS CANNABIS ADDICTIVE?
Former U.S. Surgeon General Joycelyn Elders, MD stated that Cannabis “is not physically addictive” and alluded to the damaging impact of alcohol, which is legal. However, any kind of substance that effects you on a physiological level has the capacity to be addictive; this includes things like caffeine, alcohol and even exercise. Furthermore, anything in excess can be harmful to the body, so it is important to note that appropriate administration is critical with anything.
5. HOW WILL CANNABIS BE ACCESSED, WHERE WILL IT BE SOLD?
It will be sold in retail outlets across Manitoba. As the Manitoba Government just recently gave the approval for conditional licensing, it is not known for sure where any of the retail locations will be located. However, the retail stores themselves will need to pass Government of Manitoba inspection for adherence to strict Health & Safety Standards.
6. WHO CAN PURCHASE CANNABIS?
The Province of Manitoba has ruled that individuals 19 years of age and older, with valid identification, will be able to purchase Cannabis. This reduces the opportunity for usage by children & youth.
Madras, Bertha K., “Update of Cannabis and its Medical Use.”
Massi, Paola et al. “Cannabidiol as Potential Anticancer Drug.” British Journal of Clinical Pharmacology 75.2 (2013): 303–312. PMC.
Prud’homme, Mélissa, Romulus Cata, and Didier Jutras-Aswad. “Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence.” Substance Abuse: Research and Treatment 9 (2015): 33–38. PMC.
Haroutounian, Simon & Ratz, Yael & Ginosar, Yehuda & Furmanov, Karina & Saifi, Fayez & Meidan, Ronit & Davidson, Elyad. (2016). The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: A Prospective Open-label Study. The Clinical journal of pain. 32. 10.1097/AJP.0000000000000364.
M. Kogan, et al. (2015). Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. Journal of Bone and Mineral Research. 30. 10.1002/jbmr.2513.
Blessing, Esther M. et al. “Cannabidiol as a Potential Treatment for Anxiety Disorders.” Neurotherapeutics 12.4 (2015): 825–836. PMC.
Naftali T..et al. “Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.”
Crippa JA, de Lima Osrio F, Del-Ben CM, Filho AS, da Silva Freitas MC, Loureiro SR (2008a). Comparability between telephone and face-to-face structured clinical interview for DSM-IV in assessing social anxiety disorder. Perspect Psychiatr Care 44: 241–247.
For more information, please visit the Cannabis Initiative page.